Business context and reporting period
OraSure Technologies, Inc. develops and sells diagnostic tests, oral-fluid specimen collection products, molecular collection systems through DNA Genotek (DNAG), and cryosurgical devices. This unaudited Form 10-Q reports the three months ended March 31, 2014, compared with the three months ended March 31, 2013. Unless otherwise noted, dollar amounts are in millions.
Financial performance and liquidity
| Metric | Q1 2014 | Q1 2013 / comparison |
|---|---|---|
| Net revenue | $23.54 | $21.16; up 11% |
| Gross profit / margin | $13.93 / 59% | $12.03 / 57% |
| Operating loss | $(5.62) | $(10.59) |
| Net loss | $(5.63) | $(10.23) |
| Loss per diluted share | $(0.10) | $(0.18) |
| Cash from operations | $(7.67) | $(7.67) |
| Capital expenditures | $0.65 | $0.48 |
Revenue was entirely product revenue in Q1 2014; the prior-year quarter included $0.20 million of licensing and product-development revenue. Operating expenses were $19.55 million, down from $22.62 million, primarily reflecting lower sales and marketing and research and development spending. Other income was $0.12 million; income tax expense was $0.13 million.
At March 31, 2014, cash was $84.19 million, down from $93.19 million at year-end; working capital was $96.79 million, versus $100.59 million. Current assets were $111.76 million and current liabilities $14.97 million. No interest-bearing debt is reported on the balance sheet presented. Stockholders’ equity was $154.71 million. Management stated that cash was expected to fund current operating and capital needs for at least the next 12 months.
Material changes versus the prior period
- DNAG revenue rose 46% to $5.76 million, and segment operating results improved to $0.78 million income from a $0.55 million loss. Growth reflected higher commercial sales, including sales to DNAG’s largest commercial customer, and academic-market order timing.
- OSUR revenue rose 3% to $17.78 million, while its operating loss narrowed to $6.39 million from $10.04 million.
- Product revenue growth reflected higher molecular collection, cryosurgical, OraQuick HCV, and OraQuick In-Home HIV sales. The HCV increase included a large international order from a humanitarian organization.
- Domestic professional HIV revenue fell 14%, partly due to delayed federal funding, customer ordering patterns, and winter weather. Substance-abuse testing revenue fell 19%; insurance risk-assessment revenue fell 9%.
- Gross margin improved to 59%, attributed to better overhead absorption and product mix. The net loss narrowed by $4.60 million, chiefly as revenue increased and sales and marketing expense declined.
- Cash from operations remained broadly unchanged despite the lower net loss; operating cash use included a $3.0 million decline in accrued expenses and other liabilities, largely associated with payment of incentive bonuses and other year-end accruals.
Outlook, risks, and unusual items
The filing gives no specific revenue or earnings guidance. Management cited expected resolution over the next few quarters of delayed government funding affecting some domestic professional HIV orders, but warned that future professional HIV sales could remain pressured by public-funding reductions and a shift to laboratory-based blood tests. Management viewed HCV as a growth opportunity but noted constrained public-health funding and the time needed to build demand.
Key risks include dependence on government-funded customers, variable international orders, competition and changing testing methods, product acceptance and regulatory requirements, and reliance on sole-source suppliers and third-party manufacturers. Foreign-exchange movements affect reported results; the company reported no currency hedges. Management said no goodwill impairment indicators existed at quarter-end, but future results below assumptions could lead to an impairment charge. The In-Home HIV test’s expected-returns reserve was $0.33 million at March 31; actual returns differing materially from estimates could affect results.
Revenue recognition for the OraQuick In-Home HIV test changed in December 2013: revenue is now recognized upon shipment to retailers or distributors, using estimated returns, whereas Q1 2013 revenue was recognized on consumer sales. Therefore, reported quarterly sales are not directly comparable. The filing reported no material expected adverse effect from ordinary-course legal matters, no significant change in contractual obligations or off-balance-sheet arrangements, and no material change to the risk factors in the 2013 Form 10-K.
Important facts for investors to verify
- Whether the In-Home HIV return estimates and shipment-based revenue recognition remain supportable, and how channel inventory and consumer sell-through compare.
- Whether delayed public funding, reduced testing, and substitution by laboratory tests continue to affect professional HIV sales.
- How sustainable DNAG’s growth is, including its reliance on its largest commercial customer and the timing of academic orders.
- Whether HCV and international sales repeat, given that some orders depend on government funding and can be sporadic.
- Cash consumption, operating-cost requirements, and management’s stated expectation that cash will cover needs for at least 12 months.